Abstract:The existence of an inflammatory process in the heart muscle, related to a progressive worsening of myocardial function, different etiopathogenetic mechanisms concur and often overlap, thus making the diagnosis and the therapeutic approach complex. As the COVID-19 pandemic progresses, the effects of the disease on the organ systems and in particular on the cardiovascular system are becoming more and more profound. Cardiac involvement is a well-known event with a high percentage of findings in the heart’s magnetic field, even in asymptomatic areas. There are numerous uncertainties regarding their evolution, in the long and short term, due not only to a difficult to determine the varied clinical expression and the rarely performed intramyocardial biopsy which additionally presents diagnostic problems but also in part to different clinical prognosis. Today, the new SARS-CoV-2 virus that uses the angiotensin converting enzyme 2 (ACE2) which is present at high levels in myocardial cells as its entrance it can create even severe heart injury. The pathophysiology in all of these cases can involve multiple immune and non-immune mechanisms within organs and vessels and can be occur in the clinical phases. Possible mechanisms of direct and indirect myocardial infarction in patients with COVID-19 include additional lesion and oxygen-rich and generalized inflammation response with myocardial immune hyperactivity (myocarditis). Therefore, these can occur through the excessive release of cytokines, the presence of thrombocytopenia, endocrine damage, heart failure, arrhythmias and more. Patients can show average signs of myocardial damage, and some develop spontaneous cardiac complications, such as heart failure, arrhythmias and, rarely, rare cardiogenic disorders. Pathophysiology in all of these may involve multiple mechanisms within the cytokine cephalic membrane, endocrine damage and thrombogenicity. The diagnosis of this myocardial injuri is mainly based on the myocardial enzyme troponin. This viewpoint paper explains today’s knowledge on viral myocarditis, in particular that from SARS-CoV-2 infection, if there is a connection with other possible biomolecular pathogenetic factors that can influence its natural course. In fact, it is for this reason that the pathogenetic mechanisms are analyzed and described. At the same time, its possible interaction with other parameters that are documented risk factors for cardiovascular disease was examined. Although these biomolecular findings were mainly related to necrotic parts of the myocardium, it is important to recognize that myocardial damage early for a better approach and prognosis.

Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart

Cardiac SARS-CoV-2 Infection, Involvement of Cytokines in Postmortem Immunohistochemical Study

Inflammatory Activation and Immune Cell Infiltration Are Main Biological Characteristics of SARS-CoV-2 Infected Myocardium.

Evidence of autoinflammation as a principal mechanism of myocardial injury in SARS-CoV-2 PCR-positive medical examiner cases

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

SARS-CoV-2 induced myocarditis: Current knowledge about its molecular and pathophysiological mechanisms

Infiltrating monocytes drive cardiac dysfunction in a cardiomyocyte-restricted mouse model of SARS-CoV-2 infection

COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies

Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart

Cardiomyocytes Recruit Monocytes Upon SARS-CoV-2 Infection by Secreting CCL2

Collagen‐Specific HSP47 + Myofibroblasts and CD163 + Macrophages Identify Profibrotic Phenotypes in Deceased Hearts with SARS‐CoV‐2 Infections

Proinflammatory cytokines driving cardiotoxicity in COVID-19

Late Cardiac Pathology in Severe Covid-19. A Postmortem Series of 30 Patients

Myocardial Pathology in COVID-19-Associated Cardiac Injury: A Systematic Review

Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies

Resolving the Developmental Mechanisms of Cardiac Microthrombosis of SARS-CoV-2 Based on Single-Cell Transcriptome Analysis

Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function

RNA-Seq analysis of human heart tissue reveals SARS-CoV-2 infection and inappropriate activation of the TNF-NF-κB pathway in cardiomyocytes

SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro

Atrial inflammation and microvascular thrombogenicity are increased in deceased COVID-19 patients

Cardiovascular biomarkers in patients with COVID-19